Did Exelixis use a 'trivial' modification to its cash cow to product-hop past a patent cliff ...

Researchers argue that Exelixis used a minor modification to extend patent protection on its main drug, potentially evading a major patent expiration and impacting competition in biotech.

This Wire brief sits within Fusion42's coverage of Biotech.